Study on TSR-042 in Advanced Clear Cell Sarcoma — ACCeSs

Sarcoma, Clear Cell Clinical Trial

Official title:
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma

Status Terminated

Clinical Trial Summary

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

Clinical Trial Description

Phase II, single arm, not randomized, European multicentric study designed to explore the activity of TSR-042, a human monoclonal anti-PD-1 inhibitor, in a population of patients with a diagnosis of advanced/metastatic clear cell sarcoma (CCS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04274023
Study type	Interventional
Source	Italian Sarcoma Group
Contact
Status	Terminated
Phase	Phase 2
Start date	January 29, 2024
Completion date	January 29, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04593758` - To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue	Phase 1/Phase 2
	Completed	`NCT00258687` - Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma	Phase 1